Adagio Therapeutics

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported the expansion of Phase 3 trial enrollment to include adolescents and pregnant or nursing women and decrease the protocol-specified, post-injection monitoring time.

Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial

Bicycle Therapeutics Plc - ADR

Cerevel Therapeutics Holdings Inc

Find out what these industry favorites are doing to impress investors.

3 Biotech Stocks That Soared to New Heights Last Week

Weber

The Korean gaming company is one of 10 companies that have gone public in August using a traditional initial public offering, Dealogic said.

DoubleDown Interactive Makes Its Market Debut, Wrapping Up a Slow Month for IPOs

Adagio Therapeutics Inc. is set to go public Friday, after the upsized initial public offering of the Massachusetts-based biopharmaceutical company focused on antibody-based solutions for infectious diseases priced overnight at $17 a share, in the middle of the expected range. The company raised $309.4 million as it sold 18.2 million shares, up from expectations it would sell 17.7 million shares.

Adagio Therapeutics' upsized IPO prices in middle of range, valued company at more than $1.8 billion

WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics Announces Pricing of Initial Public Offering

Adagio Therapeutics Announces Pricing of Initial Public Offering

Adagio Therapeutics has filed to raise $301 million in an IPO. The firm is developing a treatment for coronavirus diseases.

Adagio Therapeutics Pursues $301 Million IPO

News for Adagio Therapeutics Stock (ADGI)